Sign inJoin waitlistJoin the waitlist

Beth Christian

Director of the Hematology and Oncology Fellowship Program · OSUCCC – James

Credentials: · · · ·

History

Hematology and Oncology Fellowship · OSUCCC – James
Present
Education in the Department of Internal Medicine Division of Hematology · OSUCCC – James
Present
OSUCCC – James
2009–Present

The Ohio State University Wexner Medical Center
2006–2009
The Ohio State University Wexner Medical Center
2003–2005
The Ohio State University Wexner Medical Center
2002–2003
Ohio State University College of Medicine
1998–2002
Tulane University

Research

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Journal of Clinical Oncology · 2019 · 219 citations
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Blood · 2021 · 184 citations
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Blood Advances · 2017 · 138 citations

Robert Baiocchi
29 papers
Kami Maddocks
28 papers
Narendranath Epperla
27 papers
YS
Yazeed Y Sawalha
22 papers
David Bond
21 papers · 1 as a fellow
Nancy Bartlett
20 papers
Kristie Blum
17 papers
Lapo Alinari
17 papers · 1 as a resident
TV
Timothy Voorhees
17 papers · 4 as a fellow
Walter Hanel
14 papers
Audrey Sigmund
12 papers
JR
John Reneau
11 papers

Clinical trials

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
Principal investigator · Active not recruiting
Ohio State University Comprehensive Cancer Center
2018–2027
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Principal investigator · Active not recruiting · Phase 1
Beth Christian
2017–2026
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2013–2027
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
Beth Christian
2012–2019